Inflammatory bowel disease and coronary artery disease

被引：17

作者：

Sappati Biyyani R.S.R. ^{[1
,2
]}

Fahmy N.M. ^{[4
]}

Baum E. ^{[2
]}

Nelson K.M. ^{[3
]}

King J.F. ^{[4
]}

机构：

[1] MetroHealth Medical Center, Cleveland, OH 44109

[2] Canton Medical Education Foundation, Canton, OH 44710

[3] Aultman Hospital, Canton, OH 44710

[4] Gastroenterology and Hepatology Specialists Inc., Canton, OH 44718, 4360 Fulton Drive, NW

来源：

Indian Journal of Gastroenterology | 2009年 / 28卷 / 1期

关键词：

Framingham heart study; Multivariate models; Pathogenesis of atherosclerosis;

D O I：

10.1007/s12664-009-0006-3

中图分类号：

学科分类号：

摘要：

Chronic inflammation with the presence of excess serum acute-phase proteins, cytokines and cell adhesion molecules is increasingly being implicated in atherosclerosis. The association between inflammatory bowel disease (IBD) and coronary artery disease (CAD) is unstudied. This is a preliminary, thesis-generating cross-sectional study aimed at evaluating the presence of traditional atherosclerotic risk factors in patients with IBD and CAD compared with the control population. The medical records of 42 consecutive IBD patients with CAD from 1999 to 2005 (27 men) were reviewed for the Framingham risk factors. The Framingham risk score (FRS) is calculated based on age, sex, hypertension, diabetes and hyperlipidemia. FRS of patients with IBD and CAD was compared with the FRS of 137 age- and sex-matched (102 men) consecutive patients with CAD (controls). When the Framingham risk score adjusted for group and gender with age as a covariate, the adjusted total FRS score was higher in patients with CAD alone (10.0 [3.75]) as compared to those with; IBD and CAD: (8.1 [3.47]; p = 0.001). FRS is lower in cases (patients with IBD and CAD) when compared with the controls (CAD alone). © Indian Society of Gastroenterology 2009.

引用

页码：28 / 30

页数：2

共 10 条

[1]

Zoccali C., Mallamaci F., Tripepi G., Inflammatory proteins as predictors of cardiovascular disease in patients with end-stage renal disease, Nephrology Dialysis Transplantation, 19, SUPPL. 5, (2004)

[2]

Maradit-Kremers H., Crowson C.S., Nicola P.J., Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis, Arthritis Rheumatism, 52, pp. 402-411, (2005)

[3]

Shovman O., Gilburd B., Shoenfeld Y., The role of inflammatory cytokines in the pathogenesis of systemic lupus erythematosus-related atherosclerosis: A novel target for treatment?, Journal of Rheumatology, 33, 3, pp. 445-447, (2006)

[4]

Deliargyris E.N., Madianos P.N., Kadoma W., Marron I., Smith Jr. S.C., Beck J.D., Offenbacher S., Periodontal disease in patients with acute myocardial infarction: Prevalence and contribution to elevated C-reactive protein levels, American Heart Journal, 147, 6, pp. 1005-1009, (2004)

[5]

Goggins M.G., Goh J., O'Connell M.A., Weir D.G., Kelleher D., Mahmud N., Soluble adhesion molecules in inflammatory bowel disease, Irish Journal of Medical Science, 170, 2, pp. 107-111, (2001)

[6]

Wilson P.W.F., Assessing coronary heart disease risk with traditional and novel risk factors, Clinical Cardiology, 27, 6, (2004)

[7]

Ridker P.M., Wilson P.W.F., Grundy S.M., Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?, Circulation, 109, pp. 2818-2825, (2004)

[8]

Cucino C., Sonnenberg A., Cause of death in patients with inflammatory bowel disease, Inflammatory Bowel Diseases, 7, 3, pp. 250-255, (2001)

[9]

Ito H., Treatment of Crohn's disease with anti-IL-6 receptor antibody, J Gastroenterol, 40, SUPPL. 16, pp. 32-34, (2005)

[10]

Kupcova V., Turecky L., Detkova Z., Prikazska M., Keleova A., Changes in acute phase proteins after anti-tumor necrosis factor antibody (infliximab) treatment in patients with Crohn's disease, Physiological Research, 52, 1, pp. 89-93, (2003)

← 1 →